CLINICAL TRIALS PROFILE FOR EUTHYROX

All Clinical Trials for Euthyrox

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01379170 ↗	Thyroid Study Type 2 Diabetes Mellitus (T2DM)	Unknown status	Maastricht University Medical Center	Phase 4	2011-06-01	Background of the study: Thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are known to promote weight loss, which could be beneficial for treating obesity, and type 2 diabetes. Thyroid hormone treatment stimulates energy expenditure resulting in increased body heat production, in which brown adipose tissue play an important role. It is hypothesized that thyroid hormones would induce increased energy expenditure via a process called mitochondrial uncoupling, thereby creating an inefficient energy status. Indeed, an in vivo study showed a 70% increased flux through the tricarboxylic acid cycle (TCA) and an unchanged ATP synthesis rate upon T3 treatment in lean, healthy young men. The disproportionate increase in TCA flux compared with ATP synthesis suggests increased mitochondrial uncoupling. It is however unknown whether increased mitochondrial uncoupling would increase fat oxidation and exerts favorable effects on insulin sensitivity. There is compelling evidence that type 2 diabetic patients have high levels of fat accumulation in non-adipose tissues, such as skeletal muscle, heart and liver. Ectopic fat accumulation is related to insulin resistance, however, why this fat accumulates in peripheral organs is not known. Recently, studies reported compromised mitochondrial oxidative capacity in type 2 diabetic patients and first-degree relatives of diabetic patients, suggested to play an important role. Therefore, subjects suffering from overweight and/or type 2 diabetes with overt hypothyroidism form an interesting group for examining the metabolic effects of thyroid hormone treatment, as less is known about the effects of thyroid hormone treatment in these groups. Objective of the study: The purpose of this study is to evaluate whether thyroid hormone replacement therapy in type 2 diabetic patients suffering from overt hypothyroidism, will improve muscular mitochondrial function, lower ectopic fat accumulation in muscle and liver, increase brown adipose tissue activity and enhance insulin sensitivity. Study design: Type 2 diabetic patients diagnosed with hypothyroidism will undergo 3 months of thyroid hormone replacement therapy (THRT) (Euthyrox®, Merck, Germany). Patients will be metabolically characterized (such as insulin sensitivity and fat accumulation in peripheral tissues) before and after this thyroid hormone replacement therapy. Study population: 17 type 2 diabetic patients diagnosed with overt hypothyroidism (9 from the Netherlands, 8 from Germany which will only do the PET-CT) Primary study parameters/outcome of the study: Thyroid hormone-induced change in whole body insulin sensitivity (change in insulin-stimulated glucose disposal) and muscle mitochondrial function. Secondary study parameters/outcome of the study (if applicable): Thyroid hormone-induced change of lipid content in skeletal muscle and liver and brown adipose tissue activity.
NCT01458600 ↗	Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)	Completed	Mikael Lantz	Phase 4	2006-09-01	AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological changes of the retrobulbar tissue concordant with ophthalmopathy. Factors known to induce clinical symptoms of ophthalmopathy are mainly unknown. An interesting observation is that a patient with stable and inactive Graves´ disease developed ophthalmopathy when treated with a glitazone due to diabetes type 2. Glitazones have been shown to increase differentiation of orbital preadipocytes to mature adipocytes. Glitazones are PPAR-gamma agonists and recently diclofenac have been shown to interact with PPAR-gamma in physiological concentrations. Other non-steroidal antiinflammatory drugs, NSAID, like indomethacin lack this effect. In addition, diclofenac inhibit synthesis of prostaglandins which also may be of importance because the natural ligand to PPAR-gamma is prostaglandin J. Inflammation and adipogenesis are hallmarks of the pathological process in Graves ophthalmopathy and NSAID like diclofenac may affect both. There is only one earlier study demonstrating effects of NSAID (indomethacin) in 7 patients with effects on soft tissue symptoms, eye muscle symptoms and eye protrusion. Aim - to investigate if diclofenac can prevent ophthalmopathy and/or progress of ophthalmopathy. Specific aims: 1. To study the frequency of clinical ophthalmopathy in Graves´ disease after 12 months treatment with or without diclofenac. 2. To study the frequency of progress of clinical signs and symptoms in ophthalmopathy after 12 months treatment with or without diclofenac. 3. To study the frequency of optic neuropathy in clinical ophthalmopathy after 12 months treatment with or without diclofenac. Study plan and randomisation - 150 patients with newly diagnosed Graves´disease without ophthalmopathy will be treated with anti-thyroid drugs and L-thyroxin (block and replace) according to clinical routine for 18 months. These patients will be randomized to diclofenac 50 mg twice daily or not for 12 months.
NCT01848171 ↗	Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism	Active, not recruiting	Shandong Provincial Hospital	Phase 4	2013-07-01	Hypothyroidism is a common clinical entity which is often complicated by dyslipidemia. It is also reported increased risk for incidence of atherosclerosis and resulting coronary heart disease(CHD), heart failure(HF) and cardiovascular(CV) death. The effect of L-thyroxine replacement treatment on serum lipid and atherosclerosis is controversial in hypothyroid patients, especially in those with mild or moderate subclinical hypothyroidism. The present study was designed to investigate whether L-thyroxine replacement was effective in improving serum lipid profiles and retarding atherosclerosis progress.
NCT02512978 ↗	Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)	Unknown status	Beijing Anzhen Hospital	Phase 4	2015-08-01	Based on accumulating evidences showing that hypothyroid status is associated with poor prognosis among acute myocardial infarction (AMI) patients, the study is designed to evaluate whether replacement treatment with levothyroxine could have beneficial effects on patients with AMI and hypothyroidism. This is a multicenter prospective computerized-randomized trial stratified by ejection fraction with a 1:1 ratio to levothyroxine group or standard therapy group.
NCT02512978 ↗	Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)	Unknown status	Beijing Chao Yang Hospital	Phase 4	2015-08-01	Based on accumulating evidences showing that hypothyroid status is associated with poor prognosis among acute myocardial infarction (AMI) patients, the study is designed to evaluate whether replacement treatment with levothyroxine could have beneficial effects on patients with AMI and hypothyroidism. This is a multicenter prospective computerized-randomized trial stratified by ejection fraction with a 1:1 ratio to levothyroxine group or standard therapy group.

Clinical Trial Conditions for Euthyrox

Condition Name

Condition Name for Euthyrox
Intervention	Trials
Hypothyroidism	3
Subclinical hypothyroïdism	2
Intracerebral Hemorrhage	1
Low T3 Syndrome	1

Condition MeSH

Condition MeSH for Euthyrox
Intervention	Trials
Hypothyroidism	5
Endocrine System Diseases	1
Poisoning	1
Diabetes Mellitus	1

Clinical Trial Locations for Euthyrox

Trials by Country

Trials by Country for Euthyrox
Location	Trials
China	5
Netherlands	1
Sweden	1

Clinical Trial Progress for Euthyrox

Clinical Trial Phase

Clinical Trial Phase for Euthyrox
Clinical Trial Phase	Trials
Phase 4	6
Phase 1	1
NA	1

Clinical Trial Status

Clinical Trial Status for Euthyrox
Clinical Trial Phase	Trials
Unknown status	3
Completed	2
Not yet recruiting	2

Clinical Trial Sponsors for Euthyrox

Sponsor Name

Sponsor Name for Euthyrox
Sponsor	Trials
Chinese Academy of Medical Sciences, Fuwai Hospital	2
Peking Union Medical College Hospital	2
The Luhe Teaching Hospital of the Capital Medical University	2

Sponsor Type

Sponsor Type for Euthyrox
Sponsor	Trials
Other	22
Industry	1

Last updated: May 3, 2026

EUTHYROX (Levothyroxine): Clinical Trial Update, Market Position, and 2025–2035 Projection

What is EUTHYROX and what does it claim therapeutically?

Euthyrox is a brand of levothyroxine (L-T4), a synthetic thyroid hormone used to treat hypothyroidism and support thyroid hormone replacement. In practice, clinical development for levothyroxine brands is typically “lifecycle” focused (bioequivalence, formulation changes, switching) rather than new-to-world efficacy trials, because the active ingredient is established and guidelines emphasize stable dosing with product interchangeability controls.

What does the clinical trial landscape look like for Euthyrox?

For brand levothyroxine products, “clinical trials” activity usually appears in three buckets:

1. Bioequivalence studies (reference vs test product, including multiple strengths).
2. Formulation or manufacturing site changes supported by bridging/bioequivalence rather than new efficacy endpoints.
3. Switching and equivalence studies (treatment continuity when patients move between products).

For Euthyrox specifically, the publicly indexed clinical footprint is typically not dominated by large Phase 3 efficacy programs, and most brand-relevant updates are regulatory and bioequivalence filings rather than late-stage outcome trials.

Clinical trials update for Euthyrox (high level):

• Trial type mix: Bioequivalence/bridging and product switching rather than new clinical efficacy.
• Expected endpoints: PK measures (AUC, Cmax) and thyroid labs (TSH with time windows) in switching contexts.
• Regulatory pattern: Stability and interchangeability are supported through equivalence frameworks rather than novel disease-area endpoints.

What is the regulatory and safety framing that shapes trials and market demand?

Levothyroxine dosing is sensitive to:

• Strength accuracy and consistent release
• Absorption interactions (iron, calcium, PPIs, food timing)
• Product-to-product consistency that can influence TSH stability

Regulators and guideline bodies treat levothyroxine as a narrow-therapeutic-index replacement where switching can require monitoring. This affects both trial design (switching endpoints) and commercial conversion (brand loyalty for stable control).

---

Market Analysis: Where Euthyrox sits in levothyroxine

How big is the levothyroxine market and how does it split?

Levothyroxine is one of the highest-volume endocrine generics and brand products globally. The market typically splits into:

• Brand levothyroxine (premium pricing in markets where brands still capture volume, or where switching is managed with stronger brand adherence)
• Generic levothyroxine (main volume in countries with broad generic coverage and active substitution)

For a brand like Euthyrox, market performance depends on:

• Generic penetration (pricing pressure and substitution)
• Tender and reimbursement rules
• Substitution policies (pharmacy substitution acceptance)
• Patient and prescriber preference for stable TSH control

What are the commercial drivers for Euthyrox specifically?

Euthyrox’s demand drivers track the levothyroxine class:

• Hypothyroidism prevalence (especially in aging populations)
• Long-term therapy adherence
• Switching sensitivity that supports brand selection by physicians in some settings
• Formulation and strength breadth that supports prescribing convenience

Commercial headwinds:

• Generic substitution and price erosion
• Regulatory-driven interchangeability expectations
• Tender-based pricing

Where is price discipline strongest and weakest?

• Stronger price discipline: Countries where substitution is restricted or monitored closely, and where brand continuity is encouraged.
• Weaker price discipline: Markets with high generic penetration, permissive substitution, and aggressive tendering.

---

Clinical and Commercial Projection (2025–2035)

What trajectory does the Euthyrox brand market follow over 2025–2035?

The projection for Euthyrox is best modeled as a blend of:

• Therapy pool growth (hypothyroidism incidence and diagnosis rates)
• Aging-driven persistence (higher treatment prevalence)
• Ongoing generic price pressure (volume share shifts and margin compression)
• Lifecycle switching effects (brand switching within class)

Projected pattern (base case):

• Market growth (units): Modest to mid single-digit CAGR driven by prevalence and ongoing replacement therapy.
• Revenues (brand): Lower growth than unit growth due to price erosion and substitution.
• Share: Gradual loss where substitution is permissive, stable where continuity monitoring exists.

What does the sensitivity analysis imply for revenue CAGR?

Revenue outcomes hinge on three variables:

1. Substitution policy strictness (brand continuity and physician controls)
2. Generic entry intensity in Euthyrox’s core markets
3. Tender dynamics (award pricing and contract length)

Base case revenue shape (directional):

• Early to mid period: margin compression as generics expand.
• Later period: partial stabilization as the class matures and competitive intensity levels out, leaving prevalence growth to carry unit volume.

---

Competitive Landscape: Key factors that decide share

What competitive forces matter most for Euthyrox?

• Generic substitution: The core competitive threat in most countries.
• Tendering: Can rapidly shift share toward the lowest-cost suppliers.
• Formulation differences: Even within “levothyroxine,” consistent absorption and dose uniformity can influence TSH stability, supporting brand preference.
• Distribution depth: Ability to supply strengths and dosing regimens consistently.

Who wins and why?

Brand and “authorized generic” style strategies win in markets where:

• Prescribers resist substitution for sensitive patients
• Reimbursement supports brand continuity
• Switching requires monitoring that favors stable products

Generic winners gain where:

• Substitution is routine
• Monitoring burden falls on prescribers but does not materially stop substitution
• Pricing pressure dominates procurement decisions

---

Actionable R&D and Commercial Implications

What R&D actions are most likely to create regulatory value for Euthyrox-type products?

Given the class biology, the highest probability levers for brand incumbents are:

• Strength and formulation lifecycle optimization (manufacturing changes with bridging data)
• Switching and adherence evidence in target markets where substitution risk threatens continuity
• Stability and quality consistency programs to reduce recall risk and maintain prescriber confidence

What commercial actions improve resilience against generic substitution?

• Targeted prescriber and patient education emphasizing administration timing and interaction avoidance.
• Continuity programs for patients stable on the brand (where policies allow).
• Portfolio management across strengths to reduce dispensing errors and support adherence.

---

Key Takeaways

• Euthyrox is a levothyroxine brand, so the clinical pipeline is dominated by bioequivalence, switching, and lifecycle bridging rather than new efficacy Phase 3 programs.
• The market outlook is structurally shaped by hypothyroidism prevalence growth but is constrained by generic substitution and tender pressure.
• Over 2025–2035, the likely pattern is modest unit growth with slower brand revenue growth as price erosion offsets prevalence gains.
• Long-term share stability depends on substitution policy strictness, continuity monitoring, and product quality consistency.

---

FAQs

Is Euthyrox still undergoing Phase 3 clinical development?

Euthyrox-style levothyroxine brands typically do not run large Phase 3 efficacy trials for the same established indication. Brand-relevant studies usually center on bioequivalence and switching/bridging evidence.

What endpoints drive regulatory acceptance for levothyroxine brand changes?

Regulators commonly rely on pharmacokinetic bioequivalence metrics for formulation or manufacturing changes, and use thyroid control metrics (often TSH) in switching contexts.

What most affects real-world performance of levothyroxine products?

Administration timing and interactions (iron, calcium, PPIs, food), consistent dosing, and product-to-product stability drive thyroid lab outcomes.

How does substitution policy affect Euthyrox’s revenue?

Where substitution is permissive and monitored lightly, brands face faster share loss and price pressure. Where continuity monitoring exists, brands can retain higher volume and pricing.

What is the biggest market risk to Euthyrox through 2035?

Ongoing generic entry intensity and tender-driven pricing pressure, which compress brand margins faster than the underlying prevalence growth expands volume.

---

References

[1] U.S. Food and Drug Administration. Approved Drug Products: Euthyrox (levothyroxine sodium). FDA.
[2] European Medicines Agency. Product Information for levothyroxine-containing medicinal products (Euthyrox and related summaries). EMA.
[3] NICE. Hypothyroidism: assessment and management (guideline on dosing and monitoring). National Institute for Health and Care Excellence.
[4] American Thyroid Association. Guidance on levothyroxine management, monitoring, and brand/generic switching considerations. ATA.
[5] Clinically relevant levothyroxine bioequivalence and switching study frameworks (regulatory and standard PK equivalence guidance). EMA/FDA bioequivalence guidance documents.